atai Life Sciences (ATAI) –
-
Form 8-K ATAI Life Sciences N.V. For: Mar 28
-
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
-
atai Life Sciences (ATAI) Announces Positive Initial Results from Beckley Psytech’s Phase 2a Study of BPL-003
-
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
-
Form 4 ATAI Life Sciences N.V. For: Mar 13 Filed by: Kirpekar Sahil
-
Form 4 ATAI Life Sciences N.V. For: Mar 13 Filed by: Johnson Anne Nagengast
-
Form 4 ATAI Life Sciences N.V. For: Mar 13 Filed by: Rao Srinivas
-
Form 4 ATAI Life Sciences N.V. For: Mar 14 Filed by: Brand Florian
-
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
-
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
-
Form SC 13G/A ATAI Life Sciences N.V. Filed by: Apeiron Investment Group Ltd.
-
Form 8-K ATAI Life Sciences N.V. For: Feb 01
-
atai Life Sciences (ATAI) Appoints Anne Johnson as CFO
-
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
-
Form 8-K ATAI Life Sciences N.V. For: Jan 18
-
Form 4 ATAI Life Sciences N.V. For: Jan 05 Filed by: Angermayer Christian
-
Form 8-K ATAI Life Sciences N.V. For: Jan 07
-
Form 8-K ATAI Life Sciences N.V. For: Jan 04
-
Form 8-K ATAI Life Sciences N.V. For: Jan 03
-
atai Life Sciences (ATAI) Announces Strategic Investment in Beckley Psytech
-
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
-
atai Life Sciences (ATAI) Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01
-
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
-
Form 4 ATAI Life Sciences N.V. For: Nov 16 Filed by: Brand Florian
-
Form 10-Q ATAI Life Sciences N.V. For: Sep 30
-
Form 8-K ATAI Life Sciences N.V. For: Nov 14
-
atai Life Sciences (ATAI) Tops Q3 EPS by 45c
-
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
-
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
-
Form 8-K ATAI Life Sciences N.V. For: Oct 10
-
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
-
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
-
Form 8-K ATAI Life Sciences N.V. For: Sep 29
-
Form 4 ATAI Life Sciences N.V. For: Sep 13 Filed by: Brand Florian
-
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
-
atai Life Sciences to Participate in Upcoming September Investor Conferences
-
Form 8-K ATAI Life Sciences N.V. For: Aug 25
-
Form 10-Q ATAI Life Sciences N.V. For: Jun 30
-
Form 8-K ATAI Life Sciences N.V. For: Aug 10
-
atai Life Sciences (ATAI) Reports Q2, Announces Clinical Data from the Phase 1 Study of DMX-1002
-
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
-
atai Life Sciences (ATAI) Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101
-
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
-
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
-
atai Life Sciences to Participate in Upcoming June Investor Conferences
-
Form 8-K ATAI Life Sciences N.V. For: May 26
-
Form 4 ATAI Life Sciences N.V. For: May 23 Filed by: JOHNSON SABRINA MARTUCCI
-
Form 4 ATAI Life Sciences N.V. For: May 23 Filed by: Auerbach Michael
-
Form 4 ATAI Life Sciences N.V. For: May 23 Filed by: Smiley Andrea Heslin
-
Form 4 ATAI Life Sciences N.V. For: May 23 Filed by: Angermayer Christian
Back to ATAI Stock Lookup